OR WAIT null SECS
February 03, 2023
Tezspire is a biologic that specifically targets the inflammation associated with asthma.
January 11, 2023
Airsupra is the first rescue medication to manage both the symptoms and the inflammation associated with asthma.
January 05, 2023
Nirsevimab is a single-dose, long-acting antibody to protect infants from respiratory syncytial virus (RSV) lower respiratory tract infections. The FDA action date is in the third quarter of 2023.
December 07, 2022
If approved the vaccine, RSVpreF, would be available for people 60 years of age and older. The Prescription Drug User Fee Act goal date for a decision is in May 2023.
September 04, 2022
With this approval, about 300 children between 12 months and 24 months will be eligible for treatment with Orkambi.
August 03, 2022
Coherus’ Cimerli has been approved to be interchangeable for all five indications, including age-related macular degeneration and diabetic retinopathy. It will be available in early October 2022.
June 09, 2022
Two studies conducted by AllianceRx Walgreens Prime call attention to the importance of adherence for reducing risk of negative health outcomes and financial costs.
May 24, 2022
Tyvaso DPI is a dry inhalation powder and new inhalation device to treat patients with pulmonary arterial hypertension, a life-threatening disease. It is expected to be available in June 2022.
March 16, 2022
Called Breyna, this drug-device combination generic product is a metered-dose inhaler, which contains both budesonide and formoterol.
March 15, 2022
The FDA has asked for clinical data for Fasenra, which is being reviewed as a treatment for chronic rhinosinusitis with nasal polyps.